sclareol has been researched along with Triple Negative Breast Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borges, GSM; Cassali, GD; de Barros, ALB; de Souza, ÂM; Fernandes, RS; Ferreira, LAM; Leite, EA; Silva, JO; Yoshida, MI | 1 |
1 other study(ies) available for sclareol and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Diterpenes; Doxorubicin; Drug Carriers; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lipids; Mice; Mice, Inbred BALB C; Nanostructures; Triple Negative Breast Neoplasms | 2019 |